Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

April 19, 2018April 19, 2018

Sickle Cell Disease Researchers Identify a Children’s Stroke Prediction Tool

The amount of oxygen the blood loses when traveling through the brain could help identify children with sickle cell disease who are at risk of having a stroke, a ... Read more

March 27, 2018March 27, 2018

Sickle Cell Patients at Higher Risk for ER Readmission, Hospitalization, Study Finds

Patients with sickle cell disease show the highest rates of readmission and hospitalization within 30 days of being discharged from an emergency department, a single-center study found. The study, ... Read more

February 15, 2018February 15, 2018

Imara Begins Phase 2 Sickle Cell Disease Trial Testing IMR-687 in Adults

Imara, a pharmaceutical company developing new therapies for sickle cell disease (SCD), has successfully dosed the first patient enrolled in its clinical trial evaluating escalating doses of IMR-687 in ... Read more

February 8, 2018February 8, 2018

Hypersensitivity to Allergens May Increase Risk of Acute Chest Syndrome in Sickle Cell Anemia Children

Hypersensitivity to allergens in children with sickle cell anemia may increase the risk of acute chest syndrome, a study suggests. The study “Aeroallergen sensitization predicts acute chest syndrome in children ... Read more

January 9, 2018January 9, 2018

Bluebird Bio Presents Positive Early Results of Gene Therapy LentiGlobin for Sickle Cell Disease

Bluebird bio announced encouraging interim results from the ongoing Phase 1 clinical trial testing its investigational gene therapy LentiGlobin for patients with severe sickle cell disease (SCD). The results were ... Read more

November 28, 2017November 28, 2017

Expert Analysis Updates Advice on Managing Sickle Cell Retinopathy

Following a review of studies published in the last decade, experts have updated their recommendations for managing a sickle cell disease-related eye complication known as sickle cell retinopathy (SCR). ... Read more

November 7, 2017November 7, 2017

Investigational Therapy Altemia Achieves Main Endpoints in Pediatric Sickle Cell Trial

Sancilio Pharmaceuticals says its investigational therapy Altemia (SC411) achieved primary and secondary endpoints in a clinical trial with sickle cell patients 5 to 17 years old. Altemia is a combination ... Read more

August 24, 2017

Stanford Center Hopes to Take Stem Cell and Gene Therapies to a New Level

The new Stanford Center for Definitive and Curative Medicine will foster the development of stem cell and gene therapies for genetic diseases, including sickle cell anemia. More than 280 million people around ... Read more

August 17, 2017

AbbVie’s Imbruvica is First Approved Treatment for Adults with Chronic Graft-Versus-Host-Disease

The U.S. Food and Drug Administration (FDA) approved Imbruvica (ibrutinib) for treatment of adult patients with chronic graft-versus-host-disease (cGVHD) who failed to respond to other forms of systemic therapy, AbbVie announced. FDA’s ... Read more

April 18, 2017

Therapy with tPA Found to Be Safe in SCD Patients Who Have a Stroke

Patients who suffered a stroke and have sickle cell disease (SCD) can safely receive lytic therapy with tissue plasminogen activator (tPA), according to new research. The study, “Coexistent Sickle ... Read more

Pin It on Pinterest